{"id":"W2588609033","doi":"10.1093/annonc/mdw365.92","title":"SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Cancer; PI3K/AKT/mTOR pathway; Aromatase inhibitor; Oncology; Breast cancer; Placebo; Estrogen receptor; Cancer research; Aromatase; Biology; Pathology; Signal transduction; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007901923,0.001379265,0.001352026,0.0005049392,0.0002662377,0.001029318,0.001006867,0.0009571904,0.004161068],"category_scores_gemma":[0.0006048774,0.0005790744,0.001233538,0.0005214988,0.000912472,0.000817403,0.0003412123,0.002154576,0.0009856226],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001200842,"about_ca_system_score_gemma":0.001821638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003324432,"about_ca_topic_score_gemma":0.00963828,"domain_scores_codex":[0.9997982,0.00007870026,0.000007011254,0.00003193907,0.00001693885,0.00006713549],"domain_scores_gemma":[0.9997663,0.00003627763,0.0000423471,0.00002341199,0.000009564125,0.0001222373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7369898,0.03899215,0.005329459,0.001342662,0.002508251,0.0002625875,0.0003581271,0.009584056,0.06066293,0.001251858,0.01080317,0.1319149],"study_design_scores_gemma":[0.6830809,0.2853612,0.01349462,0.00005542873,0.001023644,0.0004418483,0.0001068389,0.003910759,0.006027213,0.0005967043,0.005837517,0.00006334525],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890305,0.001924678,0.0006860408,0.0007175829,0.000142823,0.00172153,0.002292918,0.0004109535,0.00307293],"genre_scores_gemma":[0.9783482,0.002711613,0.002929947,0.001013535,0.0001310462,0.002229081,0.005760881,0.00006615453,0.006809603],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004161068,"threshold_uncertainty_score":0.01392013,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02271555053021598,"score_gpt":0.3300113679872997,"score_spread":0.3072958174570837,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}